The Immunosuppressants market in Australia has been experiencing steady growth in recent years.
Customer preferences: Patients suffering from autoimmune diseases and those who have undergone organ transplants are the primary customers for immunosuppressants. With an aging population and increasing prevalence of autoimmune diseases, the demand for immunosuppressants is expected to rise in Australia. Additionally, the preference for biologic drugs that have fewer side effects and better efficacy is also driving the growth of the market.
Trends in the market: The Australian government has been implementing policies to increase access to immunosuppressants for patients. This has led to an increase in the number of prescriptions for these drugs, thereby driving the growth of the market. Furthermore, the market is witnessing a shift towards the use of biologic drugs, which have a higher cost but offer better efficacy and fewer side effects. The introduction of biosimilars is also expected to drive the growth of the market by providing more affordable options for patients.
Local special circumstances: Australia has a well-established healthcare system with a strong emphasis on universal healthcare. This has led to increased access to healthcare services, including immunosuppressants. The government has also implemented policies to increase access to these drugs, which has further driven the growth of the market. Additionally, the presence of a large aging population and a high prevalence of autoimmune diseases in the country has contributed to the growth of the market.
Underlying macroeconomic factors: Australia has a stable economy with a strong focus on research and development in the healthcare sector. This has led to the development of new and innovative drugs, including immunosuppressants. Furthermore, the country has a well-established regulatory framework for the approval of new drugs, which has helped to ensure the safety and efficacy of immunosuppressants. The government also provides subsidies for certain drugs, which has helped to increase access to these drugs for patients. Overall, these underlying macroeconomic factors have contributed to the growth of the immunosuppressants market in Australia.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
